Jun 25, 2019

Video proceedings from the fifth in a series of 6 integrated symposia held at the 2019 ONS Annual Congress. Featuring perspectives from Dr Erika Hamilton, Ms Elizabeth O’Reilly, Dr Hope S Rugo and Ms Gretchen Santos:

• Introduction (00:00)
  • Program overview: Dr Love
• HER2-Positive Localized and Metastatic Breast Cancer (BC) (2:16)
• Case (Ms O’Reilly): A woman in her late 40s with ER-positive, HER2-positive Stage IIIB inflammatory BC who received neoadjuvant treatment, had significant residual disease at surgery and began adjuvant T-DM1 (9:04)
• Case (Ms Santos): A woman in her early 60s with ER-negative, HER2-positive BC who began 1 year of adjuvant trastuzumab/pertuzumab after mastectomy but was switched to T-DM1 (12:31)
• Case (Ms Santos): A woman in her early 40s with ER-positive, HER2-positive BC who received postadjuvant neratinib on the CONTROL study (38:38)
• Case (Ms O’Reilly): A woman in her early 60s initially diagnosed with ER-positive, HER2-negative BC presents with ER-positive, HER2-positive metastatic disease to the bone, liver and brain (43:41)
• ER-Positive, HER2-Negative Metastatic Disease (55:50)
• Case (Ms Santos): A premenopausal woman in her early 50s with widespread ER/PR-positive, HER2-negative metastatic BC to the bone who underwent ovarian ablation and received palbociclib/letrozole (1:5:38)
• Case (Ms O’Reilly): A woman in her early 50s with ER-positive metastatic BC who received multiple lines of systemic treatment, including abemaciclib monotherapy (1:15:53)
• Triple-Negative Metastatic BC (1:31:31)
• Case (Ms Santos): A woman in her mid-30s with metastatic triple-negative BC who experienced a good response to pembrolizumab (1:37:46)

Select publications